PharmVar GeneFocus: CYP2C9

Sangkuhl K, Claudio-Campos K, Cavallari LH, Agundez J, Whirl-Carrillo M, Duconge J, Del Tredici AL, Wadelius M, Botton MR, Woodahl EL, Scott SA, Klein TE, Pratt VM, Daly AK, Gaedigk A. Clin Pharmacol Ther. 2021 Jun 10. doi: 10.1002/cpt.2333.

Online ahead of print.

PMID: 34109627 Review.

Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems

J. Kevin Hicks, Nihal El Rouby,Henry H. Ong, Jonathan S. Schildcrout, Laura B. Ramsey, Yaping Shi,Leigh Anne Tang, Christina L. Aquilante,Amber L. Beitelshees, Kathryn V. Blake, James J. Cimino,Brittney H. Davis, Philip E. Empey, David P. Kao,Daniel L. Lemkin, Nita A. Limdi, Gloria P. Lipori, Marc B. Rosenman, Todd C. Skaar, Evgenia Teal, Sony Tuteja, Laura K. Wiley, Helen Williams, Almut G. Winterstein, Sara L. Van Driest, Larisa H. Cavallari, Josh F. Peterson, on behalf of the IGNITE Pharmacogenetics Working Group

First published: 11 January 2021 https://doi.org/10.1002/cpt.2161

 

Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients

Laura B. Ramsey, PhD1,2Henry H. Ong, PhD3Jonathan S. Schildcrout, PhD4Yaping Shi, MS4Leigh Anne Tang, BS5J. Kevin Hicks, PharmD, PhD6Nihal El Rouby, PharmD, PhD7,8Larisa H. Cavallari, PharmD7Sony Tuteja, PharmD, MS9Christina L. Aquilante, PharmD10Amber L. Beitelshees, PharmD, MPH11Daniel L. Lemkin, MD, MS12Kathryn V. Blake, PharmD13Helen Williams, BS14James J. Cimino, MD15Brittney H. Davis, PharmD16Nita A. Limdi, PharmD, PhD, MPSH16Philip E. Empey, PharmD, PhD17Christopher M. Horvat, MD, MHA18David P. Kao, MD19Gloria P. Lipori, MT, MBA20Marc B. Rosenman, MD21,22Todd C. Skaar, PhD23Evgenia Teal, MA24Almut G. Winterstein, PhD25Aniwaa Owusu Obeng, PharmD26Daria Salyakina, PhD27Apeksha Gupta, MPH27Joshua Gruber, MPH27Jennifer McCafferty-Fernandez, PhD27Jeffrey R. Bishop, PharmD, MS28,29Zach Rivers, PharmD30Ashley Benner, MPH31Bani Tamraz, PharmD, PhD32Janel Long-Boyle, PharmD, PhD32Josh F. Peterson, MD, MPH33Sara L. Van Driest, MD, PhD33,34for the IGNITE Pharmacogenetics Working Group

JAMA Netw Open. 2020;3(12):e2029411. doi:10.1001/jamanetworkopen.2020.29411

Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

First published: 08 September 2020 https://doi.org/10.1002/cpt.2039